Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study).

Goicoechea M, de Vinuesa SG, Quiroga B, Verde E, Bernis C, Morales E, Fernández-Juárez G, de Sequera P, Verdalles U, Delgado R, Torres A, Arroyo D, Abad S, Ortiz A, Luño J.

Cardiovasc Drugs Ther. 2018 Jun;32(3):255-263. doi: 10.1007/s10557-018-6802-1.

PMID:
29943364
2.

The effect of some medications given to CKD patients on vitamin D levels.

Yuste C, Quiroga B, de Vinuesa SG, Goicoechea MA, Barraca D, Verdalles U, Luño J.

Nefrologia. 2015;35(2):150-6. doi: 10.1016/j.nefro.2015.05.016. Epub 2015 Jun 23.

3.

25 (OH) vitamin D levels and renal disease progression in patients with type 2 diabetic nephropathy and blockade of the renin-angiotensin system.

Fernández-Juárez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Lahera V, Casas L, Oliva J; PRONEDI Study Group.

Clin J Am Soc Nephrol. 2013 Nov;8(11):1870-6. doi: 10.2215/CJN.00910113. Epub 2013 Oct 17.

4.

Utility of bioimpedance spectroscopy (BIS) in the management of refractory hypertension in patients with chronic kidney disease (CKD).

Verdalles U, de Vinuesa SG, Goicoechea M, Quiroga B, Reque J, Panizo N, Arroyo D, Luño J.

Nephrol Dial Transplant. 2012 Dec;27 Suppl 4:iv31-5. doi: 10.1093/ndt/gfs420.

PMID:
23258808
5.

Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.

Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, Gutierrez E; PRONEDI Study Group.

Am J Kidney Dis. 2013 Feb;61(2):211-8. doi: 10.1053/j.ajkd.2012.07.011. Epub 2012 Aug 29.

PMID:
22939518
6.

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.

Goicoechea M, de Vinuesa SG, Verdalles U, Ruiz-Caro C, Ampuero J, Rincón A, Arroyo D, Luño J.

Clin J Am Soc Nephrol. 2010 Aug;5(8):1388-93. doi: 10.2215/CJN.01580210. Epub 2010 Jun 10.

7.

Response to 'Treatment with statins may be considered in ESRD patients for primary prevention of cardiovascular disease'

Cachofeiro V, Lahera V, Goicochea M, de Vinuesa SG, Luño J.

Kidney Int. 2009 Jun;75(12):1355. doi: 10.1038/ki.2009.111. No abstract available.

PMID:
19483752
8.

Serum fibrinogen levels are an independent predictor of mortality in patients with chronic kidney disease (CKD) stages 3 and 4.

Goicoechea M, de Vinuesa SG, Gómez-Campderá F, Aragoncillo I, Verdalles U, Mosse A, Luño J.

Kidney Int Suppl. 2008 Dec;(111):S67-70. doi: 10.1038/ki.2008.519.

9.

Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease.

Cachofeiro V, Goicochea M, de Vinuesa SG, Oubiña P, Lahera V, Luño J.

Kidney Int Suppl. 2008 Dec;(111):S4-9. doi: 10.1038/ki.2008.516. Review.

PMID:
19034325
10.

Endothelial dysfunction, oxidative stress and inflammation in atherosclerosis: beneficial effects of statins.

Lahera V, Goicoechea M, de Vinuesa SG, Miana M, de las Heras N, Cachofeiro V, Luño J.

Curr Med Chem. 2007;14(2):243-8. Review.

PMID:
17266583
11.

Dual blockade of the renin-angiotensin system in the progression of renal disease: the need for more clinical trials.

Fernandez-Juárez G, Barrio V, de Vinuesa SG, Goicoechea M, Praga M, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S250-4. Review.

12.

Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease.

Goicoechea M, de Vinuesa SG, Lahera V, Cachofeiro V, Gómez-Campderá F, Vega A, Abad S, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S231-5.

13.

Insulin resistance, inflammatory biomarkers, and adipokines in patients with chronic kidney disease: effects of angiotensin II blockade.

de Vinuesa SG, Goicoechea M, Kanter J, Puerta M, Cachofeiro V, Lahera V, Gómez-Campderá F, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S206-12.

14.

Oxidative stress in uremia: the role of anemia correction.

Lahera V, Goicoechea M, de Vinuesa SG, Oubiña P, Cachofeiro V, Gómez-Campderá F, Amann R, Luño J.

J Am Soc Nephrol. 2006 Dec;17(12 Suppl 3):S174-7. Review.

15.

Effects of erythropoietin on left ventricular hypertrophy in adults with severe chronic renal failure and hemoglobin <10 g/dL.

Ayus JC, Go AS, Valderrabano F, Verde E, de Vinuesa SG, Achinger SG, Lorenzo V, Arieff AI, Luño J; Spanish Group for the Study of the Anemia and Left Ventricular Hypertrophy in Pre-dialysis Patients.

Kidney Int. 2005 Aug;68(2):788-95.

16.

The reno-protective effect of the dual blockade of the renin angiotensin system (RAS).

Luno J, Praga M, de Vinuesa SG.

Curr Pharm Des. 2005;11(10):1291-300. Review.

PMID:
15853685
17.

Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors.

de Vinuesa SG, Ortega M, Martinez P, Goicoechea M, Campdera FG, Luño J.

Kidney Int Suppl. 2005 Jan;(93):S44-7.

PMID:
15613068
18.

Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD).

Goicoechea M, de Vinuesa SG, Gómez-Campderá F, Luño J.

Kidney Int Suppl. 2005 Jan;(93):S35-8.

PMID:
15613066
19.

Efficacy of moxonidine in the treatment of hypertension in obese, noncontrolled hypertensive patients.

Abellán J, Leal M, Hernández-Menárguez F, García-Galbis JA, Martínez-Pastor A, de Vinuesa SG, Luño J.

Kidney Int Suppl. 2005 Jan;(93):S20-4.

PMID:
15613062
20.

Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.

Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.

Kidney Int Suppl. 2002 Dec;(82):S47-52.

21.

Angiotensin II type 1 receptor blockade to control blood pressure in postmenopausal women: influence of hormone replacement therapy.

Fernández-Vega F, Abellán J, Vegazo O, De Vinuesa SG, Rodríguez JC, Maceira B, de Castro SS, Nicolás RR, Luño J.

Kidney Int Suppl. 2002 Dec;(82):S36-41.

22.

Acute renal failure after bacteraemia and endocarditis.

Carretero D, Pérez-Flores I, de Vinuesa SG, Luño J, Valderrábano F.

Nephrol Dial Transplant. 2001 Nov;16(11):2265-6. No abstract available.

PMID:
11682682
23.

Leucopenia, hypoxia and complement activation in haemodialysis. Three unrelated phenomena.

de Vinuesa SG, Resano M, Luño J, Gonzalez C, Barril G, Junco E, Valderrabano F.

Proc Eur Dial Transplant Assoc. 1983;19:159-67.

PMID:
6878230

Supplemental Content

Loading ...
Support Center